When faced with the possibility of missed findings, would patients generally agree to consuming oral contrasts?
Most outpatients would accept drinking oral contrast material if it has diagnostic benefit, according to a study published in the Journal of the American College of Radiology.
Researchers from University of Michigan in Ann Arbor performed a prospective survey to determine how patients valued the use of oral contrast material when undergoing abdominopelvic CT.
A total of 218 patients completed the survey, in which the subjects were given a hypothetical choice to not drink oral contrast. Eighty-nine percent of the subjects (193 patients) stated that they would always drink the contrast for fear of missing an important finding, and only 2% (5 patients) stated that they would never drink it regardless of risk.
Nine percent (20 patients) said that the decision to drink oral contrast would depend on the level of risk, with 8% (18 patients) indicating that they would accept a 0.01% to 1.00% risk for missing an important finding if they did not have to drink oral contrast.
The researchers also asked about the tolerability of the oral contrast; 55% (120 patients) rated the oral contrast taste as tolerable and 10% (21 patients) rated it bad or terrible.
Thirty-six subjects experienced concern or unease when they learned that they had to drink oral contrast:
• 8 minimal concern or unease
• 15 mild
• 10 moderate
• 3 extreme
Thirty-six patients experienced oral contrast–induced nausea or abdominal discomfort:
• 10 minimal
• 15 mild
• 10 moderate
• 1 extreme
The researchers concluded that most patients will drink oral contrast if it has any diagnostic benefit.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.